Waters (WAT) Q3 2015 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2015 earnings summary
14 Oct, 2026Executive summary
Q3 revenue was $501M, up 9% on a constant-currency basis and 2% reported; growth reflected broad-based demand for core products and services.
Revenue growth was 11% constant currency through 9M 2015; the new CEO identified continued operating execution, customer engagement, and preparation for 2016 as transition priorities.
Financial highlights
Q3 non-GAAP diluted EPS rose 3% to $1.42 from $1.38; GAAP EPS was $1.40 versus $1.34. 9M non-GAAP diluted EPS increased 12% to $3.94 from $3.51.
Q3 non-GAAP gross margin was 58.7% versus 59.0%; 9M margin was 58.5% versus 57.9%.
SG&A was flat as reported; on a constant-currency basis it grew about in line with revenue in Q3, while 9M SG&A growth trailed revenue growth slightly. R&D expense rose 13% reported.
Q3 free cash flow was $114M after $25M of capital spending; 9M free cash flow was $384M versus $324M in 9M 2014.
Outlook and guidance
Q4 constant-currency sales growth guided to 4%-5%; FX at then-current rates was expected to reduce growth by 5 percentage points.
Q4 non-GAAP diluted EPS guidance was $1.89-$1.99; gross margin was expected to approach 60%, with operating expenses growing moderately YoY.
FY 2015 constant-currency sales growth outlook was 8%-9%, with adjusted diluted EPS of $5.83-$5.93.
FY operating tax rate was expected to be ~13.5%, excluding any reestablishment of the U.S. R&D tax credit; renewal could add $0.02-$0.03 to EPS.
Latest events from Waters
- Broad recovery and new-product momentum drove Q4 growth and supported positive 2011 guidance.WAT
Q4 2010 - Pharma delays and India weakness slowed Q1; FY outlook still targets 2%-4% reported growth.WAT
Q1 2012 - Q2 growth outpaced expectations, with AI, innovation, and integration driving strong future outlook.WAT
U.S. All Stars Conference - Momentum from innovation, localization, and integration supports high single-digit growth outlook.WAT
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue doubled on BDS acquisition, but acquisition costs led to operating losses.WAT
Q2 2026 - Growth is fueled by innovation, premium pricing, and expanding global regulatory drivers.WAT
Leerink’s Global Healthcare Conference 2025 - Double-digit growth, innovation, and integration drive strong performance and future momentum.WAT
Jefferies Global Healthcare Conference 2026 - Q1 2026 revenue hit $1.267B with 20% EPS growth, but net loss was $72M from acquisition costs.WAT
Q1 2026 - High single-digit growth and margin expansion targeted, fueled by innovation and high-growth adjacencies.WAT
Investor Day 2025